Eli Lilly and Company (LLY) and Dermira (DERM) merger information including expected completion date and offer price are displayed in the deal information table below.
This deal was successfully consummated on February 21, 2020
The major Dermira (DERM) merger news updates & events are listed below. An invaluable data source for traders & investors looking to familiarize themselves with the Eli Lilly and Company (LLY) takeover of Dermira (DERM) and trade the merger arbitrage spread. Following the acquisition news and events section, there is in-depth company profile. For more proprietary Merger Arbitrage Limited content and analysis on this buyout, follow this link Dermira (DERM). The current merger arbitrage spread is available on our Spread Tracker page.
Receive instant FREE access to constantly updated DERM news related to the current merger deal. Simply register by entering your email address to receive weekly publication updates.
Traders can also review similar deal information on other stocks by selecting a deal from the “Deal” menu item above. Proprietary commentary can be accessed by simply entering a ticker symbol into the search box in the menu bar above such as “DERM“, or click on a stock ticker in the tag cloud at the foot of this article. For broader takeover news on other constituents of the T20 portfolio, please see our Spread Tracker News feed.
Dermira (NASDAQ: DERM) Merger - Acquisition News and Events
Dermira Company Profile
Dermira, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older. It also develops lebrikizumab, a novel injectable humanized monoclonal antibody targeting interleukin 13 that is in Phase IIb clinical trial for the treatment of moderate-to-severe atopic dermatitis; and early-stage research and development programs in other areas of dermatology.
Dermira, Inc. has a right of first negotiation agreement with Maruho Co., Ltd. to develop and commercialize glycopyrronium tosylate for the treatment of hyperhidrosis in Japan; an agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. to develop and commercialize lebrikizumab; and a development and commercialization agreement with UCB Pharma S.A. to develop Cimzia for the treatment of psoriasis. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California.
